Research programme: TAM receptor tyrosine kinase targeting therapeutics - Celldex Therapeutics

Drug Profile

Research programme: TAM receptor tyrosine kinase targeting therapeutics - Celldex Therapeutics

Alternative Names: TAM RTK - Celldex Therapeutics

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Salk Institute
  • Developer Celldex Therapeutics Inc; Salk Institute
  • Class Antibodies
  • Mechanism of Action Axl receptor tyrosine kinase modulators; Receptor protein-tyrosine kinase modulators; TYRO3 receptor protein tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Infections

Most Recent Events

  • 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
  • 10 Sep 2014 Kolltan Pharmaceuticals acquires Xetrios Therapeutics
  • 10 Sep 2014 Early research in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top